• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $RXRX

    Recursion Pharmaceuticals Inc.

    Subscribe to $RXRX
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: recursion.com

    Peers

    $ABSI

    Recent Analyst Ratings for Recursion Pharmaceuticals Inc.

    DatePrice TargetRatingAnalyst
    5/22/2023$8.00Equal-Weight
    Morgan Stanley
    3/16/2023$17.00Buy
    Needham
    9/16/2022$20.00Overweight
    KeyBanc Capital Markets
    4/18/2022$10.00Buy → Neutral
    BofA Securities
    3/4/2022$32.00 → $10.00Outperform → Market Perform
    SVB Leerink
    12/8/2021$30.00 → $32.00Outperform
    SVB Leerink
    9/21/2021$37.00Buy
    Berenberg
    8/16/2021$33.00 → $30.00Outperform
    SVB Leerink
    See more ratings

    Recursion Pharmaceuticals Inc. SEC Filings

    See more
    • SEC Form 8-K filed by Recursion Pharmaceuticals Inc.

      8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      5/9/25 5:27:47 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B7 filed by Recursion Pharmaceuticals Inc.

      424B7 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      5/9/25 5:26:22 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Recursion Pharmaceuticals Inc.

      S-8 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      5/5/25 6:07:27 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Recursion Pharmaceuticals Inc.

      10-Q - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      5/5/25 6:02:27 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      5/5/25 6:01:30 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Recursion Pharmaceuticals Inc.

      DEFA14A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      4/28/25 4:03:25 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Recursion Pharmaceuticals Inc.

      DEF 14A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      4/28/25 4:02:13 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      3/18/25 8:01:29 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 144 filed by Recursion Pharmaceuticals Inc.

      144 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      3/6/25 11:55:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Recursion Pharmaceuticals Inc.

      424B5 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)

      2/28/25 7:26:38 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Recursion Pharmaceuticals Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

      Salt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion's Board of Directors, effective as of March 15th."I am delighted to welcome Elaine and Namandjé to Recursion's Board," said Chris Gibson, Ph.D., Recursion Co-Founder and CEO. "As the company continues to grow its clinical pipeline and enhance its platform, our new Board members' scientific, clinical, business and financial expertise will be an incredible resource in support of our continued success."Dr. Namandjé N. Bumpus served as the

      3/18/25 8:00:00 AM ET
      $DVAX
      $RXRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Altitude Lab Startups Raise $154M in Capital

      SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Today, Altitude Lab announced that its incubating startups have collectively raised $154 million in early-stage funding since its launch in 2020. Founded by Recursion, Altitude Lab supports diverse life science entrepreneurs in Utah by providing fully equipped laboratories, access to investors, business operations education, and a collaborative founder community.In addition, Altitude Lab awarded its inaugural Gibson Founder Fellowship to Carmen Kivisild, Ph.D., CEO and founder of Elnora AI. The fellowship provides early-career scientists with up to $150,000 in funding, scientific support, and mentorship to accelerate the growth of their sta

      2/18/25 11:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iambic Therapeutics Appoints Michael Secora, Ph.D. as Chief Corporate Development Officer and Chief Financial Officer

      Dr. Secora is formerly the CFO and Executive Leader of Value Translation at Recursion Iambic Therapeutics, a clinical-stage biotechnology company developing novel medicines using its AI-driven discovery and development platform, announced that Michael Secora, Ph.D. will be its Chief Corporate Development Officer and Chief Financial Officer. Dr Secora will lead Iambic's finance and corporate development activities, helping frame its growing pipeline and industry-leading platform to potential partners, investors, and other stakeholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250106188573/en/Michael Secora, PhD, Chief Cor

      1/6/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities

      Brings together Recursion's scaled biology exploration and translational capabilities with Exscientia's precision chemistry design and small molecule automated synthesis capabilities to create a leading technology-first, end-to-end drug discovery platformCombined business positioned to leverage latest advances in the life sciences and technology to deliver better novel treatments to patients, faster and at a lower cost relative to traditional drug discovery and development methodsHighly complementary pipeline with approximately 10 clinical readouts expected over the next 18 monthsIndustry-leading portfolio of pharma partnerships with the potential for approximately $200 million in milestone

      8/8/24 7:39:25 AM ET
      $EXAI
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board

      SALT LAKE CITY, May 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Robert Hershberg, M.D., Ph.D, has been appointed the new Chair of the Board of Recursion, effective at the end of this term, as Martin Chavez exits after more than four years of leadership. "I'm excited to bring my clinical and scientific expertise to support Recursion's growth as Chair of the Board," said Dr. Hershberg. "In my opinion, the intersection of scientific rigor and technology to drive novel programs is the future of drug discovery and I believe Recursion will be a leader in this emerging sp

      5/24/24 4:30:00 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer

      SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer. Dr. Khan will lead Recursion's research and development, and build its emerging commercial capabilities. She has also been appointed to Recursion's Board of Directors. "Najat brings a unique blend of leadership in biological, chemical, and medical sciences, data science, and business," said Chris Gibson, Co-Founder and CEO of Recursion. "More importantly, she has a vision and passion for transforming drug disco

      4/16/24 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Announces Plans to Open New Office in London

      LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced plans to open a new office in London's vibrant King's Cross neighborhood. Set to formally open in June 2024, the site will provide Recursion and Valence Labs, the company's artificial intelligence research engine, access to world-class talent across Europe's rapidly growing TechBio sector and embed Recursion in a thriving innovation ecosystem of leading technology and life science companies. "As Recursion continues to lead and define the TechBio industry, it's critical we hire the best possible talent, much of which

      3/11/24 4:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer

      SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has appointed David Mauro, M.D., Ph.D, as its Chief Medical Officer. Dr. Mauro will lead Recursion's pipeline into and through clinical development, including its five programs currently in the clinic, beginning June 1. "We are incredibly excited to have Dr. Mauro join our team at Recursion at such an important time in the development of our clinical pipeline," said Chris Gibson, Ph.D., Co-founder and CEO at Recursion. "With his extensive background in oncology drug development and a proven track record of

      5/16/23 8:30:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Recursion Pharmaceuticals Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley initiated coverage on Recursion Pharmaceuticals with a new price target

      Morgan Stanley initiated coverage of Recursion Pharmaceuticals with a rating of Equal-Weight and set a new price target of $8.00

      5/22/23 7:50:41 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Needham initiated coverage on Recursion Pharmaceuticals with a new price target

      Needham initiated coverage of Recursion Pharmaceuticals with a rating of Buy and set a new price target of $17.00

      3/16/23 9:18:01 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • KeyBanc Capital Markets initiated coverage on Recursion Pharmaceuticals with a new price target

      KeyBanc Capital Markets initiated coverage of Recursion Pharmaceuticals with a rating of Overweight and set a new price target of $20.00

      9/16/22 7:27:04 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Pharmaceuticals downgraded by BofA Securities with a new price target

      BofA Securities downgraded Recursion Pharmaceuticals from Buy to Neutral and set a new price target of $10.00

      4/18/22 9:18:46 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Pharmaceuticals downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Recursion Pharmaceuticals from Outperform to Market Perform and set a new price target of $10.00 from $32.00 previously

      3/4/22 6:15:28 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink reiterated coverage on Recursion Pharmaceuticals with a new price target

      SVB Leerink reiterated coverage of Recursion Pharmaceuticals with a rating of Outperform and set a new price target of $32.00 from $30.00 previously

      12/8/21 4:39:39 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Berenberg initiated coverage on Recursion Pharmaceuticals with a new price target

      Berenberg initiated coverage of Recursion Pharmaceuticals with a rating of Buy and set a new price target of $37.00

      9/21/21 7:04:07 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink reiterated coverage on Recursion Pharmaceuticals with a new price target

      SVB Leerink reiterated coverage of Recursion Pharmaceuticals with a rating of Outperform and set a new price target of $30.00 from $33.00 previously

      8/16/21 5:39:12 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink initiated coverage on Recursion Pharmaceuticals with a new price target

      SVB Leerink initiated coverage of Recursion Pharmaceuticals with a rating of Outperform and set a new price target of $33.00

      5/11/21 8:08:39 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • JP Morgan initiated coverage on Recursion Pharmaceuticals with a new price target

      JP Morgan initiated coverage of Recursion Pharmaceuticals with a rating of Neutral and set a new price target of $32.00

      5/11/21 7:31:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Recursion Pharmaceuticals Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Recursion to Participate in Upcoming Investor Conferences

      Salt Lake City, May 30, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Jefferies Global Healthcare Conference — Thursday, June 5, 2025 Goldman Sachs 46th Annual Global Healthcare Conference — Tuesday, June 10, 2025 TDCowen 4th Annual Tools/Dx Revolution Conference — Monday, June 23, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com. About RecursionRecursion (NASDAQ:RXRX) is a clinical stage TechBio company leading the space by decoding biology to

      5/30/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion to Participate in Upcoming Investor Conferences

      Salt Lake City, May 06, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: Bank of America 2025 Health Care Conference — Tuesday, May 13, 2025 JP Morgan Global Technology, Media and Communications Conference — Thursday, May 15, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com.  About RecursionRecursion (NASDAQ:RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the

      5/6/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Reports First Quarter 2025 Financial Results and Provides Business Update

      Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 clinical programs and 1 preclinical program following a strategic, data-driven reviewPartnerships: Achieved fourth milestone in Sanofi collaboration, generating $7 million for an orally active small-molecule lead with best-in-class potential in autoimmune diseasesPlatform and Operations: Implemented meaningful synergies and streamlined operations while maintaining capabilities, resulting in cash runway until mid 2027 SALT LAKE CITY, May 05, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX) a le

      5/5/25 6:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

      In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp burden at the Week 13 assessment at time of data cutoff.Five of six patients (83%) experienced reductions in polyp burden ranging from 31% to 82%, however, one patient showed a substantial increase from baseline.At Week 13, 50% of patients (3 out of 6) achieved ≥1-point improvement in Spigelman stage, a measure of upper GI disease severity.The early safety profile of REC-4881 was generally consistent with that of prior MEK1/2 inhibitors; among 19 patients across Phase 1b and 2, most treatment-related adverse events were Grade 1 or 2, with Grade 3 events in 16% of patients and no Grade ≥4

      5/4/25 12:45:00 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

      Salt Lake City, UT, April 28, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2025 financial results on Monday, May 5, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on May 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/LYZwaVdPJidC7x259. Abo

      4/28/25 8:27:07 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion to Present Preliminary Clinical Data from the Ongoing Phase 1b/2 trial of REC-4881 in FAP at Digestive Disease Week 2025

      Salt Lake City, UT, April 22, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, will present preliminary data during the 2025 Digestive Disease Week (DDW) meeting from its ongoing Phase 1b/2 clinical trial, TUPELO, which is evaluating the safety and preliminary activity of REC-4881 for the treatment of familial adenomatous polyposis (FAP). The data will be presented as a late-breaking oral presentation during the Research Forum session on Hereditary GI cancer syndromes on Sunday, May 4, 2025 in San Diego. "We are pleased that DDW has recognized the importance of our data in addressing the unmet needs o

      4/22/25 8:34:17 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HealthVerity Partners with Recursion to Enhance Clinical Trial Analytics with Real-World Data

      PHILADELPHIA, April 16, 2025 /PRNewswire/ -- HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, has licensed its real-world data to enhance clinical trial design and analytics. Through this agreement, Recursion will integrate HealthVerity de-identified data for over 340M covered lives within the US into its advanced data science and machine learning platforms, the Recursion OS, allowing for deeper ins

      4/16/25 8:30:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

      Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced the generation of screening libraries leveraging tools within its AI/ML platform, the Recursion OS, with Enamine's REAL Space, the world's largest source of make-on-demand small molecules. Together, the two companies have curated 10 enriched screening libraries from over 15,000 newly synthesized compounds designed to accelerate drug discovery against 100 key and clinically relevant drug targets in difficult to address biological areas. Enamine's REAL Space represents the continuously expandi

      4/9/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

      Salt Lake City, UT, April 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in the Phase 1 EXCELERIZE clinical study evaluating REC-3565 for the treatment of relapsed or refractory B-cell lymphomas. "REC-3565 showed durable tumor regressions in preclinical studies, both as a monotherapy and in combination with a BTK inhibitor. Leveraging our AI-powered Recursion OS platform, which combines physics-based modeling with molecular dynamics and hotspot analysis, we delivered a lead candidate in just 15 months," said Najat Khan, Chief R&D Officer and C

      4/8/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion to Participate in Upcoming Investor Conference

      Salt Lake City, UT, April 01, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today its participation in the following upcoming investor conference: Needham 24th Annual Virtual Healthcare Conference — Monday, April 7, 2025 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com. About RecursionRecursion (NASDAQ:RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate o

      4/1/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Recursion Pharmaceuticals Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      11/12/24 4:57:06 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      11/12/24 10:34:18 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      11/4/24 4:16:21 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      11/4/24 1:27:55 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc.

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      10/18/24 10:59:49 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Recursion Pharmaceuticals Inc.

      SC 13G - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      7/8/24 4:17:30 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc. (Amendment)

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      2/13/24 5:12:20 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc. (Amendment)

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      2/12/24 12:21:25 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Recursion Pharmaceuticals Inc.

      SC 13G - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      2/9/24 9:49:31 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Recursion Pharmaceuticals Inc. (Amendment)

      SC 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)

      1/29/24 5:25:49 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Recursion Pharmaceuticals Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief R&D Commercial Officer Khan Najat covered exercise/tax liability with 3,796 shares, decreasing direct ownership by 0.53% to 708,585 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      5/19/25 4:44:24 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Taylor Ben R covered exercise/tax liability with 11,908 shares, decreasing direct ownership by 1% to 830,191 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      5/19/25 4:44:12 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Gibson Christopher covered exercise/tax liability with 36,197 shares, decreasing direct ownership by 3% to 1,081,253 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      5/19/25 4:44:03 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Taylor Ben R covered exercise/tax liability with 26,571 shares, decreasing direct ownership by 3% to 842,099 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      4/3/25 4:38:14 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Li Dean Y was granted 2,268 shares, increasing direct ownership by 3% to 79,618 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      4/3/25 4:37:52 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Dar Zavain was granted 2,745 shares, increasing direct ownership by 3% to 110,877 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      4/3/25 4:37:01 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Executive Officer Gibson Christopher sold $836,987 worth of shares (138,574 units at $6.04), decreasing direct ownership by 11% to 1,117,450 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      3/28/25 4:52:57 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Taylor Ben R covered exercise/tax liability with 7,057 shares, decreasing direct ownership by 0.81% to 868,670 units (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      3/19/25 4:27:38 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Sun Elaine D was granted 36,549 shares (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      3/19/25 4:27:16 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Bumpus Namandje was granted 36,549 shares (SEC Form 4)

      4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)

      3/19/25 4:27:28 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Recursion Pharmaceuticals Inc. Financials

    Live finance-specific insights

    See more
    • Recursion to Report First Quarter 2025 Business Updates and Financial Results on May 5th

      Salt Lake City, UT, April 28, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2025 financial results on Monday, May 5, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on May 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/LYZwaVdPJidC7x259. Abo

      4/28/25 8:27:07 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

      Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its fourth quarter and full year 2024 financial results on Friday, February 28, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on February 28, 2025 at 8:30 am ET / 6:30 am MT / 1:30 pm GMT. The company will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://bit

      2/24/25 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

      REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagementConfirmed partial response (PR) observed during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in advanced setting, durable response ongoing after more than 6 months of treatmentAdditional 4 patients demonstrated a best response of stable disease (SD) for up to 6 months of treatmentPlans to continue monotherapy dose escalation and initiate combination studies in 1H 2025 SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) --

      12/9/24 6:00:00 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

      Salt Lake City, UT, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its Q3 2024 financial results on Wednesday, Nov 6, 2024, following the close of the financial markets.  The company will not host its normal L(earnings) Call in relation to the business updates and financials for the third quarter. Instead, the company expects to host an update call after the anticipated close of the proposed business combination with Exscientia, which is expected to be on Nov 20, 2024. We will broadcast the live stream from Recursion's X (formerl

      10/30/24 8:22:19 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th

      Salt Lake City, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, following the close of the financial markets.  Recursion will host a L(earnings) Call on August 8, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time, interacting with a broad public audience around notable business developments and offering opportunities to ask questions. Recursion will broadcast the live stream from Recursion's X (formerly Twitter), LinkedIn and YouTube accounts. This event is free, open t

      8/5/24 4:01:00 PM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9

      SALT LAKE CITY, May 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide business updates and report its first quarter 2024 financial results on Thursday, May 9, 2024, following the close of the financial markets. Additionally, Recursion will host its quarterly L(earnings) Call on May 9, 2024 at 5:00 pm Eastern Time / 3:00 pm Mountain Time. A L(earnings) Call is Recursion's take on interacting with a broad public audience around notable business developments and offering opportunities to ask questions. Recursion will broadcast the live stream from Recursion's X (for

      5/2/24 8:00:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • AI in Healthcare: Unveiling the Future with a 42.20% CAGR Through 2029

      USA News Group Commentary VANCOUVER, BC, April 25, 2024 /PRNewswire/ -- Across several sectors the use of artificial intelligence (AI) is making a huge impact, with healthcare emerging as possibly receiving the largest boost. According to a new research report from analysts at Mordor Intelligence, the market for artificial intelligence in health care is set to explode at a CAGR of 42.20% through 2029. As the tech sector races to provide the market with solutions, several companies are emerging as leaders in aiding the healthcare sector, including Avant Technologies Inc. (OTC:AVAI), Microsoft Corporation (NASDAQ:MSFT) (NEO:MSFT), Health Catalyst, Inc. (NASDAQ:HCAT), Ginkgo Bioworks Holdings,

      4/25/24 8:01:00 AM ET
      $DNA
      $HCAT
      $MSFT
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Computer Software: Programming Data Processing
      Technology
    • Recursion Signs Lease With Vestar for an Additional 100,000 sf of Space at the Gateway in Downtown Salt Lake City

      SALT LAKE CITY, July 1, 2021 /PRNewswire/ -- Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced that it is doubling the size of its headquarters at The Gateway in downtown Salt Lake City, signing a new lease with Vestar for an additional 100,000 square feet. The Gateway is a mixed-use lifestyle and entertainment district, featuring 1.2 million square feet of retail, dining and office space as well as 1,200 multifamily units.

      7/1/21 8:54:00 AM ET
      $RXRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care